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Abstract  
Objectives To perform a systematic review to determine the effectiveness of interventions 
designed to reduce potentially inappropriate prescribing (PIP) in community-dwelling older 
people. 
 
Design Systematic review and narrative synthesis.  
 
Setting Primary and community care. 
 
Participants Community-dwelling older people. 
 
Measurements 
The primary outcome was change in PIP, as measured using either implicit or explicit tools. 
Studies were grouped into organisational, professional, financial, regulatory and 
multifaceted interventions.  
 
 
Results  
12 RCTs were identified with baseline PIP prevalence of 18% to 100%. Four out of six 
organisational interventions reported a reduction in PIP, particularly through pharmacists 
conducting medication reviews. The evidence for the effectiveness of multidisciplinary 
teams was weak. Both professional (i.e. targeting prescriber's directly) interventions were 
computerised clinical decision support interventions and were effective in decreasing newly 
prescribed PIP but not existing PIP. Three out of four multifaceted approaches were 
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effective in reducing PIP. The risk of bias was often high, particularly in reporting selection 
bias.  
 
Conclusion Interventions including organisational (pharmacist interventions), professional 
(computerised clinical decision support systems) and multifaceted approaches appear 
beneficial in terms of reducing PIP. However, the range of effect sizes reported are modest 
and it is unclear if such interventions can result in clinically significant improvements in 
patient outcomes. Ongoing assessment of interventions to reduce PIP is needed in 
community-dwelling older people, particularly in relation to preventing PIP initiation. 
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Introduction  
Older people are among the highest consumers of prescription medication and evidence 
suggests that prescribing in this population can be potentially inappropriate.1 Potentially 
inappropriate prescribing (PIP) comprises a number of suboptimal prescribing practices 
including inappropriate dose or duration of medications, drug-drug interactions, drug-
disease interactions and the use of medications that carry a significant risk of an adverse 
drug event (ADE).1, 2 Older people are more likely to have multimorbidity and be taking a 
number of medications (polypharmacy) and consequently, are more vulnerable to 
medication errors, adverse events and PIP.  
 
Several criteria have been developed to quantify the appropriateness of prescribing. These 
criteria can be categorised as either explicit (criterion-based) or implicit (judgement-based). 
Explicit criteria are specific statements of appropriateness that are generally drug or disease 
orientated and commonly focus on specific drugs to avoid.1 The US Beers criteria are the 
most commonly used explicit criteria for measuring PIP,3 and the European Screening Tool 
for Older Peoples Prescriptions (STOPP) criteria has become increasingly popular in recent 
years.4  Implicit measures are based on clinical judgement. The most commonly used 
implicit criteria is the Medicines Appropriateness Index (MAI), which assesses the 
appropriateness of prescribing across 10 elements: indication, effectiveness, dose, correct 
directions, practical directions, drug-drug interactions, drug-disease interactions, 
duplication, duration and cost.5  
 
The scale of the PIP problem has been well documented in older patients using both explicit 
and implicit criteria, with the prevalence of PIP in community dwelling older patients 
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estimated to be anywhere between 20 and 50%.6-8 PIP has been found to be associated with 
increased morbidity, ADEs, lower health related quality of life, hospitalisations and 
expenditure.7, 9-11  
 
As global populations age, PIP in older people is an important public health concern, 
particularly in primary care where the majority of prescribing for older people takes place. A 
number of interventions have been developed and tested to reduce PIP across healthcare 
settings. Recent systematic reviews have examined the evidence on interventions to 
decrease PIP in nursing home settings.12-15 These reviews have produced mixed results, and 
due to the heterogeneity of included studies, robust conclusions about the effectiveness of 
such intervention are lacking.13-15 Where strategies were found to be effective within the 
hospital or nursing home setting, there is little evidence to suggest that these would be 
effective for community dwelling older patients. The aim of this systematic review is to 
identify and determine the effectiveness of interventions to reduce PIP in community 
dwelling older people.   
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Methods 
The PRISMA guidelines for the conduct and reporting of systematic reviews and meta-
analyses were adhered to in the conduct of this systematic review.16  
 
Data sources and search strategy 
A literature search was performed including PubMed, Embase, Scopus and the Cochrane 
library databases (including the Central Register of Controlled Trials, Database of Systematic 
Reviews and Database of Abstracts of Reviews of Effect) in June 2014 (updated January 
2015) using combinations of key words and MeSH terms (Figure 1). No language or date 
restrictions were applied.  Hand searches of the references of retrieved full-text articles 
supplemented this search. 
 
Study selection and data extraction 
Studies were included if they met the following inclusion criteria:  
1. Included community dwelling older adults (≥65 years or had an average age of ≥65 
years) as the population of interest. Studies where >20% of the subject population 
were described as institutionalised (e.g. nursing homes, residential care homes or 
geriatric inpatients) were excluded.  
2. An intervention intended to improve PIP in primary care, including but not restricted 
to: organisational, professional, financial, regulatory or multifaceted interventions 
compared to usual care or alternate intervention (see Table 1 for definitions). 
7 
 
3. The primary outcome was change in PIP measured using specified implicit or explicit 
tools (e.g. Beers, STOPP, MAI). Studies that focussed on the reduction of 
inappropriate prescribing in one drug class only were also excluded. 
4. Study design was randomised controlled trials (RCT) only.  
No language restrictions were applied. Studies were assessed against the inclusion criteria 
by three reviewers (AQ, CH, CF) by reading titles and/or abstracts. Eligible studies were read 
fully in duplicate and their suitability for inclusion was independently determined (RG, BC). 
Disagreement was managed by consensus. Data were extracted on study characteristics 
(setting, duration, outcome etc.) and participant demographics (age, gender etc.). Where 
available, data on secondary outcomes such as patient reported health status (e.g. 
psychosocial outcomes: quality of life, psychological health: well-being, physical health: 
adverse drug events), health behaviour (e.g. medication compliance) and resource use (e.g. 
health service utilisation, costs) were extracted.    
 
Data synthesis 
The studies identified were too heterogeneous in terms of their outcome measures and 
intervention types to conduct a meta-analysis so a narrative summary was performed. 
Where appropriate, crude odds ratios and absolute risk reductions (ARR) were calculated. 
Interventions were categorised by the standard taxonomy of interventions developed by 
The Cochrane Effective Practice and Organization of Care Group (EPOC) including 
organisational, professional, financial and regulatory interventions, with the addition of 
multifaceted interventions (Table 1). 17  
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Ongoing studies 
Where published protocols were identified during the search, study authors were contacted 
to ascertain if results were available for inclusion in the review. Where results were not 
available, ongoing studies were described in terms of methods, intervention used and 
outcome measures, together with an estimate of the reporting date, where available 
(Appendix 1).  
 
Assessment of risk of bias  
Three authors (BC, CH, AQ) independently assessed risk of bias using the Cochrane 
Collaboration’s risk of bias tool including the standard domains of sequence generation, 
allocation concealment, blinding, outcome data, selective outcome reporting, protection 
against contamination, performance of baseline measurement and sample size. In cases of 
disagreement, a fourth reviewer (RG) was consulted. Some of the review authors were 
involved in the conduct of an RCT included in this review (the OPTI-SCRIPT study). The data 
extraction and methodological quality assessment was conducted independently by a 
researcher not involved in the review team (LM).  
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Results 
Included studies 
749 unique records were screened, and 30 full texts were reviewed. 11 RCTs met the 
inclusion criteria (Figure 1). Two studies were identified from conference 
abstracts/published protocols, one of which the review authors were involved in so study 
information was available, bringing the total of included studies to 12. The study author was 
contacted for details on the second protocol identified (Appendix 1).  
 
Study description 
Six studies were conducted in North America,18-23 five in Europe,24-28 and one in New 
Zealand.29 The mean age of the 156,529 included patients ranged from 65 to 81 years (Table 
2). Participants were eligible if they were community dwelling in all studies, had 
polypharmacy (defined as ≥3 or ≥5 drugs) in five studies18, 19, 24, 25, 29 and were at high risk for 
medication-related adverse events in one study.23 Included studies consisted of five patient 
randomised designs with sample sizes ranging from 81 to 59,860,18-20, 23, 26 and seven cluster 
studies with 13 to 107 clusters randomised.21, 22, 24, 25, 27-29 All but three studies compared the 
intervention to usual care (Table 2).21, 25, 27 Three studies made reference to intervention 
design, 20, 27, 28 with one study publishing the intervention design and pilot process 
separately, referencing a specific theoretical framework for the intervention design.28, 30 
Process evaluations to explore intervention implementation and enactment were conducted 
in three studies. 18, 19, 28 All studies were funded by government bodies, university 
departments or professional bodies. 
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PIP measurement  
Baseline PIP prevalence ranged from 18% to 100%. PIP was measured using implicit criteria 
in four studies and eight studies used explicit criteria. The MAI was the only implicit 
measure used. Three studies used a summated MAI score 19, 24, 29 and one reported the MAI 
score in terms of number of prescriptions with inappropriate medications.23 Of the eight 
studies using explicit criteria, one used the Beers criteria 1997 iteration,21 and one the 2003 
iteration.26 The McLeod criteria was used in one study.22 The remaining five studies used 
combinations of existing criteria or study specific criteria.18, 20, 25, 27, 28  
 
Risk of bias  
Studies were heterogeneous with regard to risk of bias (Figure 2). 
Detection, attrition and reporting bias were low in most studies. Randomisation, allocation 
concealment, and blinding were less reliably implemented or reported. Seven cluster 
designs ensured no contamination of control patients. 21, 22, 24, 25, 27-29 Protection against 
contamination was unclear in three patient randomised studies, 18, 20, 26 with one study 
finding it introduced no impact on the outcome.18 All cluster RCTs had accounted for 
clustering so there were no unit of analysis errors.21, 22, 24, 25, 27, 29 One RCT presented 
descriptive analysis only.26 Half of the included studies reported an adequate sample size to 
detect a difference between groups.18-20, 25, 27, 28 
  
Effects on medication appropriateness by intervention category  
All studies could be divided into organisational (n=6), professional (n=2) or multifaceted 
interventions (n= 4) (Table 2). No study involved financial or regulatory interventions.  
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Organisational interventions  
The six organisational studies included four pharmacist interventions, 19, 23, 25, 29 and two 
multidisciplinary teams (MDT) approaches.18, 26 Out of six studies, four reported a positive 
effect on PIP (Table 3).  
 
In three out of four pharmacist intervention studies, a pharmacist conducted a medication 
review with the patient and provided feedback either in person or in writing to the family 
physician.19, 23, 29 All three studies reported a significant improvement in PIP with a mean 
improvement of -3.9 to 0.37 in MAI scores1 post intervention in favour of the intervention 
group (Table 3).19, 23, 29 Bryant et al found this approach resulted in an improvement in mean 
MAI scores, however, this study had a very high withdrawal rate, retaining with only 39% of 
recruited pharmacists.29 In the remaining pharmacist intervention, Denneboom et al found 
shared pharmaceutical care (a pharmacist and family physician developed a patient 
pharmaceutical care plan together) resulted in significantly more appropriate prescribing 
than written feedback at 6 months, but this effect was not sustained at 9 months.25  
 
The remaining organisational interventions involved a MDT approach. 18, 26 Allard et al 
reported no significant decrease in PIP following a medication review case conference 
involving two physicians, a nurse and a pharmacist.18 Lampela et al reported that 
comprehensive geriatric assessment by two physicians, two nurses and two physiotherapists 
significantly changed overall prescribing in older patients (unadjusted OR 1.9, 95% CI 1.3-
2.8).26 The appropriateness of those changes was analysed descriptively and although PIP 
                                                     
1
 The MAI assesses appropriateness of a given medication across 10 elements of prescribing quality: indication, 
effectiveness, dose, correct directions, practical directions, drug-drug interactions, drug-disease interactions, 
duplication, duration and cost. Each medication is allocated a score for each element, the scores are then 
added together to give a single summated MAI score. 
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reductions were noted, particularly the use of amitriptyline and diazepam, the significance 
of those reductions was not reported.26  
Professional interventions  
Two studies were identified as professional interventions (i.e. targeting prescriber's 
directly). Both were computerised clinical decision support systems (CDSS) interventions 
which were effective (Table 3). Support was implemented at either the point of prescribing 
22 or at the pharmacy level.20 In both cases, CDSS was found to be effective in reducing new 
PIP.20, 22 Raebel et al reported a 16% relative risk reduction and this effect was largely 
attributable to reductions in dispensings amitriptyline.20  Tamblyn et al also demonstrated a 
significant reduction in patients receiving new PIP (relative risk 0.82, 95% CI 0.69 - 0.98), 
however, no effect on the discontinuation of existing PIP was noted.22   
  
Multifaceted interventions  
Four multifaceted (combining two or more techniques) interventions were identified.21, 24, 27, 
28 Rognstad et al found peer academic detailing with audit and feedback to be effective in 
reducing PIP (10.3%, 95% CI 5.9 -15.0 reduction relative to baseline).27 The largest 
reductions were seen for drugs such as  tricyclic antidepressants (TCAs) and ‘old’ 
antihistamines.27 The OPTI-SCRIPT study also found that PIP was reduced by academic 
detailing, medicines review with web-based pharmaceutical treatment algorithms that 
provided alternative treatment options, and tailored patient information leaflets, 
particularly in the appropriate prescribing of proton pump inhibitor (adjusted OR 0.3, 95% CI 
0.1 - 0.7).28 In a population where drug-specific alerts were in operation, Simon et al 
analysed the effect of age-specific computerised alerts alone, and in combination with 
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intensive academic detailing.21 They found that age-specific alerts resulted in a continuation 
of the effects of drug-specific alerts. Group academic detailing did not enhance the effect of 
the alerts. Using implicit criteria, Bregnhoj et al found a combined educational meeting with 
prescribing feedback resulted in a mean overall MAI change of -5. 24  
 
Effects on secondary outcomes: patient health status and behaviour  
Three pharmacist interventions studies involving medication review, found no significant 
benefit on the psychosocial outcome of patient quality of life (SF-36).19, 23, 29 In the only 
study powered to detect a difference, Bryant et al noted a significant decrease in the SF-36 
domains of emotional role and social functioning in the intervention group which they 
attributed to the high withdrawal rate of pharmacists in the study leaving patients feeling 
abandoned.29 One multifaceted intervention had no significant effect on patient 
psychological health in terms of well-being (WBQ-12). Pharmacist interventions had no 
significant impact on the physical health outcome of ADEs in one study. 19 
 
In terms of patient behaviour, one multifaceted intervention had no significant effect on 
beliefs about medication necessity.28 One of two pharmacist intervention studies reported a 
significant improvement in medication compliance 19, 23.  
 
Effects on secondary outcomes: health service utilisation and resource use (costs) 
Health service utilisation was assessed in two studies, 23, 28 with one reporting a reduction in 
hospitalisations but not emergency department visits.23 The data analysis is ongoing in the 
second study.28 Two studies conducted economic evaluations. Denneboom et al found that 
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both shared pharmaceutical care and written feedback showed modest savings regarding 
medication costs but this was not statistically significant.25 The data analysis is ongoing in 
the second study.28  
 
Process evaluations 
Of three process evaluations conducted, two incorporated quantitative and qualitative 
data.19, 28 All studies assessed intervention implementation 18, 19, 28 with one study finding 
that two of the three components of a multifaceted intervention were utilised. Physicians 
were receptive to the intervention in two studies. 19, 28  
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Discussion   
This systematic review identified 12 RCTs of interventions to reduce PIP in community 
dwelling older people. There was considerable variation in the types of interventions with 
small numbers of studies grouped together. Overall, four out of six organisational 
interventions reported an improvement in PIP, particularly through pharmacists conducting 
medication reviews. The evidence for the effectiveness of MDTs was weak. Both 
professional interventions were CDSS studies and were effective in decreasing new PIP but 
not existing PIP. Three out of four multifaceted approaches were effective in reducing PIP.  
 
A variety of interventions can be effective in improving prescribing practice and medication 
safety, including CDSS, educational outreach and audit and feedback.31-34  Consistent with 
these findings and previous reviews of PIP specific interventions in other healthcare 
settings, this review found various strategies may be useful in reducing PIP.1, 12, 15, 35 This 
would suggest that PIP is amenable to change, however, there was a range of modest effect 
sizes. Regardless of the explicit criteria utilised, absolute risk reductions of less than 3% 
were common. The largest absolute risk reduction was 25% in a study where all participants 
had PIP at baseline.28 There was evidence to suggest that certain drug classes responded 
better to certain interventional strategies as TCAs and ‘old’ antihistamines were reduced by 
multifaceted interventions,27 and CDSS,20 while appropriate prescribing of proton pump 
inhibitors improved with a multifaceted intervention.28 In all studies, these drugs were the 
most frequently occurring in the patient population so a significant effect was arguably 
more likely to be found.  Both CDSS studies were effective in decreasing the initiation of PIP, 
but not the discontinuation of existing PIP, while three pharmacist medication review 
studies were effective in increasing the appropriateness of current prescribing. It is unclear 
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if this reflects differences in the areas where the interventions can be effective, or 
differences in applying explicit or implicit criteria. Most studies using the MAI criteria 
reported an improvement in appropriateness across all ten elements. The largest overall 
decrease was a mean MAI change of 5 points. However, it is difficult to determine what the 
clinical importance of a change in MAI score is as it unclear what impact a reduction in score 
has on actual patient risk and outcomes such as quality of life or ADEs. A reduction in PIP, 
measured using implicit or explicit criteria, may not equate to a change in health 
outcomes.35, 36 
 
Few studies examined the impact of interventions on patient outcomes or patient 
preferences, which may be of greater importance to patients overall. This may reflect the 
difficulty in selecting such outcomes as until the recent publication of the CONSORT 
guidelines on patient-reported outcomes in RCTs, guidance has been lacking.37 Three studies 
that demonstrated an improvement in MAI scores using a pharmacist intervention did not 
report an effect on quality of life or ADEs.19, 23, 29 While higher MAI scores have been found 
to be associated with ADEs,38 there is little evidence to suggest that a decrease in MAI score 
equates to a decrease in adverse outcomes. It remains unclear if this is an effect of the 
studies being underpowered to detect differences in patient outcomes, the follow-up period 
being too short to detect a difference, or the outcome measures not being responsive to the 
intervention.  
 
While various strategies may reduce PIP, little attention has been paid to understanding 
how or why interventions worked or failed. In order to develop feasible and appropriate 
interventions, they should be theoretically informed, modelled and pilot tested prior to RCT 
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implementation, and the long-term implementation evaluated.39 This review has highlighted 
a deficit in intervention development and evaluation. Little detail on intervention 
development, underlying theoretical frameworks, and pilot studies was given, even in the 
more recent publications, a common issue in behaviour change interventions.40, 41 Very few 
studies in this review conducted a process evaluation to gain insight into the intervention 
implementation. Such evaluations can also offer insights into how study findings can be 
generalised to other settings. In relation to multifaceted interventions, too few studies were 
identified to draw conclusions about which combinations of interventions may be most 
effective.       
 
Strengths and weaknesses of this review  
This review is timely as the prevalence of PIP remains high in community dwelling older 
people.  However, there are some limitations. Potential limitations in the search strategy 
arise from the diversity in MeSH terms and key words used to describe interventions and 
PIP. Furthermore, publication bias is an important source of potential bias in systematic 
reviews. RCT designs were included in this review. While this may have resulted in the 
exclusion of other studies of interest, this criterion allowed for the inclusion of more robust 
evidence as nonrandomised studies frequently report larger treatment effects than 
randomised studies.42 A broad definition of PIP was utilised and studies that focussed on the 
reduction of inappropriate prescribing in one drug class only were excluded. Due to the 
heterogeneity of the interventions and their outcome measures, a meta-analysis was not 
possible. Few studies conducted process evaluations or presented adequate detail which 
would allow for an analysis of the impact of contextual factors on intervention 
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effectiveness. Usual care can vary greatly across settings and few studies described it in 
great detail. Many studies were limited by potential bias, particularly in relation to selection 
bias, and only half of the studies had adequate sample size, undermining the robustness of 
the findings.  
 
Implications for clinical practice and future research   
A significant body of observational research has been published on PIP over the last number 
of years. There are at least 36 published tools available to assess inappropriate prescribing 
in older people. 43 Numerous individual studies have utilised these tools to establish the 
prevalence and outcomes of PIP across healthcare settings.4, 10, 38 In primary care, Opondo et 
al identified 19 studies estimating PIP prevalence using drug-age criteria, excluded wider 
criteria (e.g. drug-disease criteria).44 This may therefore be a conservative estimate. To 
improve the empirical knowledge in this field, greater emphasis on well-designed and 
rigorous RCTs of interventions to reduce PIP are necessary. Future research should provide 
detail on intervention design and evaluation processes to enable identification of elements 
of successful interventions. 
 
Increased emphasis should be placed on the selection of appropriate outcome measures, 
particularly in terms of comparability across studies as considerable variation in the 
application of implicit and explicit measures was identified. Although the interventions 
reviewed here appear beneficial in terms of reducing PIP, the clinical impact this may have 
on patient outcomes such as ADEs and quality of life is not known. The link between 
improved medication appropriateness based on the criteria such as MAI or Beers criteria 
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and patient-related outcomes requires further investigation. Future research should 
consider involving patients to explore patient preference in relation to PIP and interventions 
to decrease it. 
 
Future research should explore whether the differences in decreasing the initiation of PIP, 
as opposed to the discontinuation of existing PIP results from differences in the 
interventions, or differences in applying explicit or implicit criteria. 
 
Conclusions  
This review highlights various interventions including organisational (pharmacist 
interventions), professional (CDSSs) and multifaceted approaches appear beneficial in terms 
of reducing inappropriate prescribing. However, effects sizes are often small and it is 
unclear if such interventions can result in clinically significant improvements in patient 
outcomes.  
Future research should place greater emphasis on intervention development and process 
evaluations to provide rigorous evaluations that will add to understanding how effective 
interventions can be sustained and ultimately translated into improvements in patient 
outcomes, particularly in relation to preventing the initiation of PIP drugs.  
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Graphics 
Table 1 Taxonomy of interventions and studies included in this review 
Intervention  Description  Included RCTs 
Organisational 
interventions 
Involve a change in the structure of health care services 
or a change in how health care services are delivered.  
Total = 6 
Multidisciplinary 
teams (MDT) 
Creation of new team of providers of different disciplines 
or additions of new members to existing team. 
2 
(Allard,18  Lampela26) 
Pharmacist 
interventions  
An intervention delivered by a pharmacist or where a 
pharmacist is a member of the intervention team. 
4 
(Bryant,29 Hanlon,19 
Taylor,23 Denneboom25) 
Professional  Target professionals themselves directly with a view to 
improving some aspect of practice. 
Total = 2 
Computerised 
clinical decision 
support systems 
(CDSS) 
Information systems to assist clinical decision making. 
Patient characteristic matched to knowledge base, 
software algorithms generate patient specific 
recommendations for clinician.  
2  
(Raebel,20 Tamblyn22) 
Audit and 
feedback 
Any summary of clinical performance of health care over 
a specified time period, given in a written, electronic or 
verbal format.   
 
 
Academic 
detailing 
A personal visit by a trained person to a health 
professional in their own setting.                          
 
Patient-
mediated 
1. New clinical information collected from patient & given 
to provider 
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approach 2. Information provided to patients to change interaction 
with provider. 
Local consensus 
process 
Inclusion of all providers in discussion to ensure 
agreement on importance and approach to chosen 
problem.  
 
Financial 
interventions 
Changes in reimbursement/payment mechanisms  Total = 0 
Provider 
orientated 
Changes to the ways providers are reimbursed, 
incentivised and penalised. 
 
Patient 
orientated  
Interventions include approaches such as the use of co-
payments and user fees. 
 
Regulatory 
interventions 
Change to professional practice and patient outcomes 
through regulation or law. 
Total = 0 
Multifaceted 
interventions  
Combine a number of professional, organisational, 
financial or regulatory interventions within a single 
intervention: 
Total = 4 
 
CDSS and academic detailing Simon21   
Education and feedback  Bregnhoj24 
Academic detailing and audit and feedback  Rognstad27 
Academic detailing, medicines review and patient 
information leaflets  
Clyne28 
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Table 2 Characteristics of Studies  
Author 
(Year, country) 
Study 
Design 
 
Study 
Duration  
Number of Participants 
Intervention Type and Comparison  Outcome Measures Results  Healthcare 
Professionals  
Patients 
Organisational interventions  
Allard 
18
  
(2001, Canada) 
RCT 
12 
months 
N/A 
266 (≥75 years, 
≥3 drugs) 
Intervention 136 
Control 130 
 
Baseline PIP: 
Intervention 
56.7% 
Control 61.2% 
 
MDT: Team of 2 physicians, 1 pharmacist 
and 1 nurse reviewed medications in a 
case conference, mailed feedback to 
family physician 
Comparison: Usual care (normal social and 
health care services) 
Primary: Number of PIP 
drugs (Quebec 
consensus panel) 
 
Secondary:  
Number of drugs taken 
per day  
 
Primary: No effect on decreasing 
PIP (adjusted OR 1.83, 95% CI 0.94 -
3.57) 
 
Secondary:  
Mean number of drugs per patient 
declined by 0.24 in intervention and 
0.13 in control (P > 0.05)  
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Lampela
26
 
(2010, Finland) 
RCT 
12 
months 
N/A 
781 (≥75 years) 
Intervention 404 
Control 377 
 
Baseline PIP: 
Intervention 
21.4% 
Control 19.5% 
MDT: Team of 2 physicians, 2 nurses and 2 
physiotherapists performed a 
comprehensive geriatric assessment 
including medication review and clinical 
examination 
Comparison: Usual care  
a) Medication 
changes 
b) Number of PIP 
drugs (Beers 
criteria 2003)  
a) 83.7% of intervention patients 
had changes to regular 
medication compared to 
72.8% in control (unadjusted 
OR 1.9, 95% CI 1.3-2.8) 
b) Descriptive analysis of PIP 
Number of PIP drugs 
decreased by 15.6% in 
intervention compared to 
2.9% in control.  
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Bryant
29
 (2011, 
New Zealand) 
Cluster 
RCT 
6 
months  
Pharmacists 
26  
GPs 63  
498 (≥65 years, 
≥5 drugs) 
Intervention 269 
Control 229 
 
Baseline PIP: 
Intervention 
mean MAI = 5.1 
Control mean 
MAI = 4.5 
Pharmacist interventions: Pharmacist 
conducted medication review, met with 
family physician to discuss 
recommendations 
Comparison: Usual care. After 6 months 
the control group received the 
intervention  
Primary:  
a) Change in MAI 
score 
b) Quality of life (SF-
36) 
 
Secondary:  
a) Change in overall 
medicine use 
b) Recommendations 
implemented 
Primary:  
a) MAI score improved more in 
intervention (mean change -
2.0) than in control (mean 
change -0.3; P = 0.003) 
b) Improvement in emotional role 
(13.4 unit difference, P = 0.024) 
and social functioning (7.7 unit 
difference, P = 0.019) for 
control. No effect on other 
domains.  
Secondary:  
a) More medication were started 
in the control group than the 
intervention group (P < 0.0001); 
more dosage reductions and 
medicine switches in the 
intervention group than the 
control group (P = 0.037). 
b) 46% of recommendations were 
implemented, 16% partially 
implemented 
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Hanlon
19
 (1996, 
USA) 
RCT 
13 
months  
 
N/A 
208 (≥65 years, 
≥5 drugs) 
Intervention 105 
Control 103 
 
Baseline PIP: 
Intervention 
mean MAI = 17.7 
Control mean 
MAI = 17.6 
Pharmacist interventions: Pharmacist 
conducted medication review, written 
recommendations sent to family physician; 
patient counselling at each clinic visit 
Comparison: Usual care. Pharmacist 
reviewed prescribing and written 
recommendations were filed for review at 
study completion.  
Primary:  
Change in MAI score 
 
Secondary:  
a) Quality of life (SF-
36) 
b) ADEs 
c) Medication 
compliance 
 
Primary: MAI score improved more 
in intervention (mean change -4.9) 
than in control (mean change -1.1; 
P<0.001) 
 
Secondary:  
a) No significant difference 
between groups in SF-36 
change scores  
b) No significant difference 
between intervention and 
control in ADEs  (30.2% V 
40.0%, P=0.19) 
c) No significant difference 
between groups in medication 
compliance 
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Taylor
23
  
(2003, USA) 
RCT 
12 
months  
N/A 
81  
(≥18 years, mean 
age 65) 
Intervention 41  
Control 40 
 
Baseline PIP: 
Not reported 
Pharmacist interventions: Pharmacist 
conducted medication review, provided 
family physician with recommendations 
and also provided patient education 
Comparison: Usual care 
a) MAI (expressed as 
number of PIP 
drugs) 
b) Quality of life (SF-
36) 
c) Health service 
utilisation 
d) Medication 
compliance 
e) Clinical outcomes 
a) Descriptive analysis of PIP  
The % of inappropriate 
prescriptions decreased in 
all 10 MAI domains in 
intervention group and 
increased in five domains 
in the control group. 
b) No significant difference 
between groups in SF-36 
c) Fewer hospitalisations (11 
V 2, P=0.003) and ED visits 
(4 V 6, p=0.044) in 
intervention patients 
compared to control  
d) Medication compliance 
scores improved in the 
intervention group but not 
in the control group 
(p=0.115). 
e) Compared to control, 
intervention patients were 
more likely to have 
35 
 
Denneboom
25
 
(2007, The 
Netherlands) 
Cluster 
RCT 
6, 9 
months 
Pharmacists 
29  
GPs 84  
738 (≥75 years, 
≥5 drugs) 
Pharmaceutical 
care 387 
Written Feedback 
351  
 
Baseline PIP: 
Not reported 
Pharmacist interventions: Shared 
pharmaceutical care, family physician and 
pharmacist developed pharmaceutical 
care plan for patient 
Comparison: Written-feedback group - 
pharmacists listed all recommendations 
per patient and delivered them to family 
physician 
Primary: Number of 
medication changes 
following clinically 
relevant 
recommendations 
(own criteria based on 
existing published) 
Secondary: Costs 
Primary: More clinically relevant 
medication changes made in 
pharmaceutical care plan group 
than feedback (42 vs 22 changes, 
P=0.02).  
This was still significant at 6 months 
(36 vs 19 changes, p=0.02) but not 
at 9 months (33 vs 19 p=0.07). 
 
Secondary: Both groups showed 
modest savings regarding 
medication costs but there was no 
statistically significant difference 
between groups 
Professional interventions 
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Raebel
20
 (2007, 
USA) 
RCT 
12 
months 
N/A 
59,860  
(≥65 years) 
Intervention 
29,840  
Control 
 29,840 
 
Baseline PIP: 
Not reported 
CDSS: Age-specific alerts sent to 
pharmacists prior to dispensing when 1 of 
11 PIMs prescribed; pharmacists phoned 
prescriber to suggest alternatives 
Comparison: Usual care - prescribing and 
dispensing per usual clinical practice 
Number of PIP drugs 
dispensed across 11 
indicators  
(Beers criteria, Zhan 
criteria) 
1.8% of intervention versus 2.2% of 
control had newly dispensed PIP (P 
= 0.002).  
 
Dispensing rates differed 
between groups for amitriptyline 
(P<0.001; 37% RRR) and diazepam 
(P=0.02; 21% RRR) 
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Tamblyn
22
 
(2003, Canada) 
Cluster 
RCT 
13 
months 
107 
Intervention 
54 Control 
53 
 
 
12,560  
(≥66 years) 
Intervention 
6,284  
Control 6,276  
 
Baseline PIP: 
Intervention 
31.8% 
Control 33.3% 
CDSS: Point of prescribing age-specific 
alerts for 159 prescribing problems, 
including drug-disease interactions, drug-
drug interactions, drug-age interactions, 
and drug duplication 
Comparison: Usual care 
Initiation and 
discontinuation rates of 
PIP 
(McLeod criteria) 
New PIP was significantly lower 
(18%) in intervention than control 
group (RR 0.82, 95% CI 0.69 - 0.98).  
 
No effect on discontinuation of pre-
existing PIP (RR 1.06, 95% CI 0.89–
1.26). 
Multifaceted interventions  
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Clyne
28
 
(2013, Ireland) 
Cluster 
RCT 
12 
months  
GP practices 
21 
Intervention 
11 
Control 10 
196 (≥70 years,    
≥ 1 drug) 
Intervention 99 
Control 97 
 
Baseline PIP: 
100%  
Multifaceted: Pharmacist led academic 
detailing, GP-led medicines review 
supported by web-based pharmaceutical 
treatment algorithms with alternatives to 
PIP; and patient information leaflets 
Comparison: Usual care 
Primary:  
a) Proportion of 
patients with PIP 
(34 criteria from 
based Beers, 
STOPP) 
b) Mean number of 
PIP drugs at 
intervention 
completion  
 
Secondary: 
a) Drug specific 
outcomes 
b) Patient beliefs 
about medication 
(BMQ) 
c) Patient Well-being 
(WBQ-12) 
Primary: 
a) 52% of intervention compared 
to 77% of control had PIP 
(adjusted OR 0.3, 95% CI 0.1 - 
0.7, P=0.02) 
b) Mean number of PIP drugs in 
the intervention was 0.7 and 
1.2 in control (P0.02) 
Number of PIP drugs per person 
less in intervention than control 
(IRR 0.71, 95% CI 0.5 to 1.0, 
P=0.49) 
 
Secondary: 
c) 23% of intervention compared 
to 47% of control had a proton 
pump inhibitor (adjusted OR 
0.3, 95% CI 0.1-0.6, P0.04). No 
significant difference between 
groups in benzodiazepines or 
therapeutic duplication 
d) No significant difference 
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Rognstad
27
 
(2013, Norway) 
Cluster 
RCT 
24 
months 
 
CME groups 
81  
Intervention 
41 Control 
40  
 
GPs 465  
Intervention 
265 Control 
209 
81,810  
(≥70 years) 
Intervention 
46,737  
Control 35,073 
 
Baseline PIP: 
Intervention 
19.9% 
Control 18.6% 
Multifaceted: Peer academic detailing on 
PIP with audit and feedback 
Comparison: Peer academic detailing on 
antibiotics with audit and feedback 
Changes in PIP across 
13 indicators  
(Beers criteria; Swedish 
national board of 
health and welfare) 
10.3% (95% CI 5.9 to 15.0) reduction 
relative to baseline for 13 selected 
PIMs per 100 patients  
 
Largest reductions were for TCAs 
and ‘old’ antihistamines (18.9%) 
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Bregnhoj
24
 
(2009, 
Denmark) 
Cluster 
RCT 
12 
months 
GP practices 
41  
212 (≥65 years, 
≥5 drugs) 
Group 1  79 
Group 2  61  
Control  62 
 
Baseline PIP: 
Group 1 mean 
MAI = 10.8 
Group 2 mean 
MAI = 9.1 
Group 3 mean 
MAI = 9.8 
Multifaceted: Interactive educational 
meeting with feedback 
Single: Interactive educational meeting 
Comparison: Usual care 
Changes in MAI score  
Combined intervention resulted in 
mean MAI change of -5 (95% CI -7.3 
to -2.6) 
41 
 
Simon
21
  
(2006, USA) 
Cluster 
RCT  
 
18 
months  
Clinics 13  
Doctors 126  
26,805  
(≥65 years) 
Intervention 
24,119  
Control 26,805 
 
Baseline PIP: 
Intervention 
mean 146.3 per 
10,000 
Control 155.2 per 
10,000 
Multifaceted: Point of prescribing,  age-
specific alerts for drugs to avoid with 
alternatives and academic detailing 
Comparison: Age-specific alerts for drugs 
to avoid with alternatives 
Number of times target 
PIP drugs dispensed per 
10,000 patients per 
quarter 
(Beers 1997) 
There was a decrease of 19.7 PIP 
per 10,000 in the intervention group 
compared to 13.0 per 10,000 in 
control but this was not significant 
(p=0.52) 
 
CDSS (computerised clinical decision support systems); CME (continuing medical education); CI (confidence interval); MAI (Medicines Appropriateness 
Index); MDT (Multidisciplinary teams); OR (odds ratio); N/A (not applicable); PIP (potentially inappropriate prescribing); RCT (randomised controlled trial) 
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Table 3 Table of effect sizes for primary outcomes  
Author 
(Year) 
No. of 
participants 
 
Baseline PIP 
prevalence  
PIP measurement 
continuous (mean 
MAI, 95% CI) 
PIP measurement categorical (explicit criteria) 
Odds ratio (OR) of PIP in 
intervention versus control  
(95% CI)
a
 
Absolute risk reductions 
(ARR)
b
  
Organisational  
Allard (2001) 
18
 
266 
58.9% 
MAI not utilised  Adjusted OR 1.83 (0.94 -3.57) -7.28% 
Lampela 
(2010) 
26
  
781 
20.4% 
MAI not utilised Crude OR 0.70 (0.50 – 1.03)  6% 
Bryant 
(2011) 
29
  
498 
 
Mean MAI per 
group 
Intervention: 5.1 
Control: 4.5 
Standardised mean 
difference 0.37 
MAI criteria utilised MAI criteria utilised 
Hanlon 
(1996) 
19
  
208 
 
Mean MAI per 
group 
Intervention: 17.7 
Control: 17.6 
 
Mean difference -3.9  
(-5.84, -1.96) 
Standardised mean 
difference -0.54 
MAI criteria utilised MAI criteria utilised 
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Taylor 
(2003) 
23
  
 
81  
Not reported 
Mean MAI scores not 
reported  
 MAI criteria utilised MAI criteria utilised 
Denneboom 
(2007) 
25
  
738  
Not reported 
MAI not utilised 
Data not presented Data not presented 
Professional (CDSS) 
Raebel 
(2007) 
20
  
59,860  
Not reported 
MAI not utilised Crude OR 0.84 (0.75 – 0.94)  0.3% 
Tamblyn 
(2003) 
22
  
12,560 
32.5% 
MAI not utilised Crude OR 0.81 (0.73 – 0.89) 2.5% 
Multifaceted  
Clyne (2013) 
28
 
196 
100% 
MAI not utilised Adjusted OR 0.3 (0.1 - 0.7) 25% 
Rognstad
27
 
(2013) 
81,810 
19.2% 
 
MAI not utilised Crude OR 0.95 (0.92 – 0.99) 0.7% 
Bregnhoj
24
 
(2009) 
212 
 
Mean MAI per 
group 
Group 1: 10.8 
Group 2: 9.1 
Group 3: 9.8 
Mean difference -5   
(-7.3 - -2.6) 
MAI criteria utilised MAI criteria utilised 
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Simon
21
  
(2006) 
26,805 
150.7 per 10,000 
MAI not utilised 
Data presented as rates per 
10,000 
Data presented as rates 
per 10,000 
 
a. Crude odds ratio calculated based on the number of cases of PIP in intervention and control at follow-up as 
follows: (number of participants in intervention with PIP/ number of participants in intervention with PIP)/ 
(number of participants in control with PIP/ number of participants in control with PIP). This approach does 
not account for changes from baseline 
b. Absolute risk reduction calculated as the difference between the control group’s event rate (i.e. number in 
control with PIP/total in control) and the experimental group’s event rate (i.e. number in intervention with 
PIP/total in (intervention).  
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Appendix 1: Characteristics of ongoing studies 
Cedilnik Group 
Title  Use of web-based application to improve prescribing in home-living elderly: 
A randomised controlled study protocol45 
Study 
design 
RCT 
Participants  Home dwelling adults ≥ 65 years 
Intervention Web-based application will screen for PIP using STOPP and START criteria. 
Identified potentially inappropriate prescriptions will be presented to 
participants' physicians for consideration and change. 
Outcome 
measure 
Decrease of PIP 
Start date Unknown  
 
RCT (randomised controlled trial); START (Screening Tool to Alert doctors to Right Treatment); 
STOPP (Screening Tool for Older Peoples Prescriptions)  
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Figure 1 Flow diagram of included risk studies  
 Records identified through database searching: 
1,654 
Pubmed: 204 
Embase: 633 
Cochrane: 23 
Scopus: 783 
Other sources: 11 
Duplicates identified: 905 
Unique records screened after removal of 
duplicates: 749 
Records excluded based on 
title and abstract: 719  
Full text assessed for eligibility: 30 
 
Studies included in narrative analysis: 12 
 
Full text articles excluded: 18 
Not PIP specific: 5 
Secondary analysis of data: 2 
Focus on 1 drug class only: 3 
Study population did not meet inclusion criteria: 4 
No control data: 3 
On-going study: 1 
Search terms and key words 
(inappropriate presc* OR appropriate presc* OR inappropriate 
pharma* OR suboptimal presc*)  
(Intervention Studies OR Controlled Clinical Trials as Topic OR 
Controlled Clinical Trial [Publication Type]) 
(Primary Health Care [Mesh] OR Physicians, Primary Care [Mesh] 
OR ambulatory care) 
(aged OR elderly OR community dwelling elderly OR community 
dwelling older people) 
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Allard 2001 U U U L L L L L L 
Bregnhoj 2009 L U L L L U L L H 
Bryant 2010 U U U L H L L U U 
Clyne 2013 L L H L L L U L L 
Denneboom 2007 U U U U L L L L L 
Hanlon 1996 L U L L L U L H L 
Lampela 2010 L U U U L U L L H 
Raebel 2007 L U L U L L L U L 
Rognstad 2013 U U U U L L L L L 
Simon 2006 U U U L U L L L H 
Tamblyn 2003 U U H U U L L L U 
Taylor 2003 U U U U L L L H H 
 
H high risk       L low risk       U unclear risk 
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Figure 2 Risk of bias summary  
